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Background: Recently, the co-administration of GnRH agonist and hCG for final oocyte maturation- 40 and 34 hours
prior to OPU, respectively (double trigger) was suggested as the treatment of genuine empty follicle syndrome. In
the present study, we aim to evaluate whether the double trigger improves the number of oocytes retrieved in
patients with low (<50%) number of oocytes retrieved per number of preovulatory follicles.
Methods: In this proof of concept cohort historical study, we compared the stimulation characteristics of 8 IVF
cycles, which include the double trigger to the patients’ previous IVF attempt, triggered with hCG-only.
Results: Patients who received the double trigger (study group) had a significantly higher number of oocytes
retrieved, number of 2PN, number of embryos transferred and significantly higher proportions of the number of
oocytes retrieved to the number of follicles >10 mm and >14 mm in diameter on day of hCG administration, with a
tendency toward a higher number of TQE, as compared to their previous cycles (hCG-only trigger). Three ongoing
clinical pregnancies were recorded in the study group and none in the hCG-only trigger group.
Conclusions: Co-administration of GnRH-agonist and hCG for final oocyte maturation, 40 and 34 hours prior to OPU,
respectively (double trigger), is suggested as a valuable new tool in the armamentarium for treating patients with
low/poor oocytes yield despite an apparently normal follicular development and E2 levels and in the presence
of optimal hCG levels on the day of OPU.
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Controlled ovarian hyperstimulation (COH) is considered
a key factor in the success of in vitro fertilization-embryo
transfer (IVF-ET) because it enables the recruitment of
multiple healthy fertilizable oocytes [1]. Moreover, human
chorionic gonadotropin (hCG) is usually used at the end of
COH, as a surrogate LH surge, to induce final oocyte
maturation and resumption of meiosis [2].
Lack of oocyte yield during ovum pick-up (OPU),
following COH with an apparently normal follicular de-
velopment and E2 levels and in the presence of optimal* Correspondence: raoul.orvieto@sheba.health.gov.il
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unless otherwise stated.hCG levels on the day of OPU- the genuine empty
follicle syndrome (EFS) [3], is a rare entity, with an esti-
mated prevalence of 0–1.1% [4,5]. On the other hand, a
more frequently encountered situation is the normally
responding patients with a low oocytes yield, i.e. a low
ratio (<50%) between the number of oocytes retrieved to
the number of follicles >14 mm in diameter on the day
of hCG administration.
Despite many years of clinical experience [6], the
underlying mechanism of the aforementioned conditions
is still obscure and no precise prevention methods exist
[5]. Several strategies were offered to patients with EFS
[summarized in [5]], including another standard ART
cycle; shifting from an GnRH-agonist to GnRH-antagonist
COH protocol; re-administering hCG from a differentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hCG from a urinary to a recombinant preparation; using
GnRH-agonist for final; prolonging the interval between
ovulation triggering and OPU; and follicle flushing during
oocyte retrieval [7].
Recently, a new treatment modality has been clinically
implemented to EFS patient, with the co-administration
of GnRH agonist and hCG for final oocyte maturation-
40 and 34 hours prior to OPU, respectively (double
trigger) [5]. This method combines the advantage of
both: (1) the prolongation of the time between ovula-
tion triggering and OPU; and (2) the GnRH agonist
trigger with the consequent simultaneous induction of
an FSH surge.
Prompted by this new remedy, we offered the double
trigger to all our patients, who underwent the GnRH-
antagonist COH protocol, resulting with poor oocytes
yield due to low (<50%) number of oocytes retrieved per
number of follicles > 14 mm in diameter on day of hCG
administration. In the present study, we aim to further
evaluate whether the double trigger improves the num-
ber of oocytes retrieved and the ratio between the number
of oocytes retrieved per number of follicles > 14 mm in
diameter on day of hCG administration.
Methods
All consecutive patients with poor oocytes yield, despite
normal response to COH, due to low (<50%) number
of oocytes retrieved per number of follicles > 14 mm
in diameter on day of hCG administration, who were
treated in our IVF unit during one year period were
evaluated. Of whom, only those who received in the
subsequent IVF cycle, a double trigger (GnRH-agonist
and hCG) for final follicular maturation were included.
The study was approved by the Institutional Research
Ethics Board of our center.
All patients underwent the multi-dose GnRH-antagonist
COH protocol during both IVF cycles. In both cycles,
ovulation induction was performed by the administra-
tion of recombinant FSH, started at the 2nd or 3rd day
of menses, using the same starting dose in each patient.
Once the leading follicle had reached a size of 13 mm,
or/and E2 levels exceeded 1200 pmol/L, co-treatment
with the GnRH antagonist 0.25 mg/day, was initiated
and the recombinant FSH was substituted by human
menopausal gonadotropins. Gonadotropins doses were
further adjusted according to serum estradiol levels and
vaginal ultrasound measurements of follicular diameter,
obtained every two or three days. Final follicular matu-
ration was triggered by, either:
(1) In the first IVF cycles: recombinant hCG (Chorio-
gonadotropin alfa, ovitrelle 250 mcg, Serono), 36 hours
prior to OPU, or; (2) In subsequent cycles: the co-
administration of GnRH-agonist (Triptorelin acetate,decapeptyl 0.2 mg, Ferring Pharmaceuticals, Israel) and
recombinant hCG (250 mcg), 40 and 34 hours prior to
oocyte retrieval, respectively.
Routine IVF or intracytoplasmic sperm injection (ICSI)
was then performed, as appropriate. Transvaginal ET was
performed 48 to 72 hours after OPU in both cycles. All
patients received luteal support with progesterone.
Data on patient age and infertility-treatment-related
variables were collected from the files. Ovarian stimulation
characteristics, number of follicles >10 mm and >14 mm
in diameter on day of hCG administration, number of oo-
cytes retrieved, embryo quality and number of embryos
transferred were assessed and compared between the study
(double trigger) cycle and the previous (hCG-only trigger)
control cycle.
Embryos classification was based on the individual em-
bryo scoring parameters according to pre-established
definitions [8]. While a top quality embryo (TQE) was
defined as seven or more blastomeres on day 3, equally-
sized blastomeres and <20% fragmentation, poor quality
embryos consist of all the rest. Clinical pregnancy was
defined as visualization of a gestational sac and fetal
cardiac activity on transvaginal ultrasound.
Statistical analysis was performed with Student’s paired
t-test and chi square, as appropriate. Results are
presented as means ± standard deviations; p value < 0.05
was considered significant.
Results
Eight consecutive patients were evaluated. Mean age and
body mass index during the study cycle were 38.0 ±
4.8 years and 27.7 + 5.4 kg/m2, respectively. The clinical
characteristics of the IVF cycles in the two study cycles
are shown in Table 1.
In the present study, while using the same COH
protocols which differ only in the methods of trigger-
ing final follicular maturation, as expected, no diffe-
rences were observed between the groups in the length
of stimulation, the number of gonadotropin ampoules
administered, peak estradiol and progesterone levels and
numbers of follicles >10 mm and >14 mm in diameter
on day of hCG administration. However, patients who
received the double trigger (study group) had a signifi-
cantly higher number of oocytes retrieved (7.0 ± 4.6 vs.
2.3 ± 2.5, p < 0.02), number of 2PN (6.0 ± 4.6 vs. 1.7 ± 1.2,
p < 0.002), number of embryos transferred (2.2 ± 0.7 vs.
0.85 ± 0.9, p < 0.002) and significantly higher propor-
tions of the number of oocytes retrieved to the num-
ber of follicles >10 mm (80.3% ±31.1% vs. 18.5% ± 16.6%,
p < 0.001) and >14 mm in diameter (118.0% ± 71.2% vs.
23.7% ± 21.5%, p < 0.01) on day of hCG administration,
with a tendency toward a higher number of TQE (3.7 ± 0.8
vs. 0.4 ± 0.5, p = 0.06) respectively, as compared to the
hCG-only trigger cycles.
Table 1 Comparison between IVF cycles with hCG versus double trigger (GnRH-ag + hCG)
hCG Double trigger p values
Number of gonadotropin ampoules used 38.5 ± 24.5 49.8 ± 15.4 ns
Length of stimulation (days) 10.7 ± 2.5 10.7 ± 2.2 ns
Total number of gonadotropin used 39 ± 25 49 ± 15 ns
Peak E2 levels on day of hCG administration (pmol/l) 5402 ± 1983 4642 ± 2483 ns
Progesterone levels on day of hCG administration (nmol/l) 1.7 ± 0.9 1,5 ± 0.7 ns
Number of follicles of >14 mm on day of hCG administration 8.0 ± 3.5 6.4 ± 4.3 ns
Number of follicles of >10 mm on day of hCG administration 10.6 ± 5.8 8.2 ± 4.3 ns
Number of oocytes retrieved 2.3 ± 2.5 7.0 ± 4.6 p < 0.02
Number of 2PN embryos 1.7 ± 1.2 6.0 ± 4.6 p < 0.002
Number of top quality embryos 0.4 ± 0.5 3.7 ± 0.8 p = 0.06
Number of embryos transferred 0.85 ± 0.9 2.2 ± 0.7 p < 0.002
Number of oocytes retrieved per number follicles of >14 mm on day of hCG administration (%) 23.7 ± 21.5 118.0 ± 71.2 p < 0.01
Number of oocytes retrieved per number follicles of >10 mm on day of hCG administration (%) 18.5 ± 16.6 80.3 ± 31.1 p < <0.001
Positive hCG (%) 0 (0/8) 62.5% (5/8) p < 0.001
Clinical ongoing pregnancy (%) 0 (0/8) 37.5% (3/8) p < 0.03
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none in the hCG-only trigger group (Table 1). Of which,
3 are ongoing, one resulted in a blighted ovum and one
was biochemical pregnancy.
Discussion
In the present preliminary cohort historical study, the
co-administration of GnRH agonist and hCG for final
oocyte maturation- 40 and 34 hours prior to OPU,
respectively, to patients with poor oocytes yield due to
low (<50%) number of oocytes retrieved per number of
follicles > 14 mm in diameter on day of hCG administra-
tion, resulted in significantly higher numbers of oocytes’
retrieved and embryos transferred and a significantly
higher proportion of the number of oocytes’ retrieved to
number of preovulatory follicles. Of notice, the observed
improved in oocyte yield was despite a non-significant de-
crease in the number of follicles of >14 mm and >10 mm
on day of hCG administration.
Five biochemical (positive hCG) pregnancies were
recorded in the study group (double trigger) and none in
the hCG-only trigger group. Of which, 3 (37.5%) are
ongoing and one resulted in a blighted ovum. However,
it should be emphasized that the increased pregnancy
rate in the study group (double trigger) is biased due to
the study design which offered this protocol to patients
who had failed a previous IVF attempt.
As part of a standard/conventional COH regimen,
final oocyte maturation and resumption of meiosis are
usually triggered by one bolus of hCG (5000–10,000 units),
that is administered as close as possible to the time of ovu-
lation (i.e. 36 hours before oocyte recovery) [2]. In 1990,
Gonen et al. [9] have demonstrated that ovulation may bealso triggered by GnRH agonist, causing the release of both
endogenous LH and FSH, while in 2008, Shapiro et al. [10]
have established the concept of ‘Dual trigger’, combining
both hCG and GnRH-agonists, aiming to trigger ovulation
with the questionable ability to prevent severe ovarian
hyperstimulation syndrome [11,12].
Recently, Beck-Fruchter et al. [5] have described a case
of recurrent empty follicle syndrome, successfully treated
by ovulation trigger with GnRH agonist 40 hours and hCG
added 34 hours prior to OPU. They assumed that by
prolonging the time between ovulation triggering and
OPU and the GnRH agonist trigger with the consequent
simultaneous induction of an FSH surge, the “double trig-
ger” could overcome any existing impairments in granu-
losa cell function, oocyte meiotic maturation or cumulus
expansion, resulting in successful aspiration of mature
oocytes, pregnancy and delivery.
In the present preliminary report, we further extended
the aforementioned indications to the “double trigger”
and offered it to patients with poor oocytes yield due to
low (<50%) number of oocytes retrieved per number of
follicles > 14 mm in diameter on day of hCG admi-
nistration, despite an apparently normal follicular de-
velopment and E2 levels during COH. While number of
follicles of >14 mm and >10 mm on day of hCG adminis-
tration wwere non-significantly decrease, we could dem-
onstrate a significant increase in oocytes yield, a trend
toward a higher number of TQE, with a reasonable clin-
ical pregnancy rate. These observations are in agreement
with Lin et al. [13], who compared the IVF outcome of
normal responders, undergoing triggering of final oocyte
maturation with either hCG and GnRH-agonist, both ad-
ministered 35-36 hours prior to OPU, or hCG-only. The
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cantly higher implantation, clinical pregnancy and live-
birth rates as compared with the hCG trigger group.
Conclusions
“Double trigger” is suggested as a valuable new tool in
the armamentarium for treating patients with low/poor
oocytes yield, despite an apparently normal follicular de-
velopment and E2 levels and in the presence of optimal
hCG levels on the day of OPU. Further large prospective
studies are needed to elucidate the aforementioned re-
commendation in this and other situations, such as pa-
tients with high proportion of immature oocytes or poor
responder patients, prior to its routine implementation.
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